-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on WAVE Life Sciences, Raises Price Target to $20

Benzinga·11/11/2025 14:58:30
Listen to the news
Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and raises the price target from $18 to $20.